Dosimetry in clinical radionuclide therapy: the devil is in the detail

  • Francesco Giammarile
  • Kristoff Muylle
  • Roberto Delgado Bolton
  • Jolanta Kunikowska
  • Uwe Haberkorn
  • Wim Oyen
Letter to the Editor

Notes

Compliance with ethical standards

Conflict of interest

None.

Research involving human participants and/or animals

This is not a research article.

Informed consent

No informed consent was needed.

References

  1. 1.
    Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, et al. Clinical radionuclide therapy dosimetry: the quest for the "holy gray". Eur J Nucl Med Mol Imaging. 2007;34(5):772–86.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Chiesa C, Sjogreen Gleisner K, Flux G, Gear J, Walrand S, Chouin N, et al. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2017.  https://doi.org/10.1007/s00259-017-3707-3.PubMedCentralGoogle Scholar
  3. 3.
    DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol. 2001;39:203–18.CrossRefPubMedGoogle Scholar
  4. 4.
    Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Pouget J-P, Mather SJ. General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med. 2001;28:541–61.CrossRefPubMedGoogle Scholar
  6. 6.
    Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biological bystander effect elicited in vitro by targeted radiopharmaceuticals labelled with α-, β-, and auger electron-emitting radionuclides. J Nucl Med. 2006;47:1007–15.PubMedGoogle Scholar
  7. 7.
    Granzotto A, Devic C, Viau M, Maalouf M, Joubert A, Massart C, et al. Individual susceptibility to radiosensitivity and to genomic instability: its impact on low- dose phenomena. Health Phys. 2011;100(3):282.CrossRefPubMedGoogle Scholar
  8. 8.
    Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol. 2012;13(1):65–77.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.European Association of Nuclear Medicine, BoardViennaAustria
  2. 2.Faculty of Medicine, Lyon SudUniversity of LyonLyonFrance
  3. 3.Department of Nuclear MedicineUniversity Hospital Brussels / UZ Brussel (VUB)BrusselsBelgium
  4. 4.Department of Diagnostic Imaging and Nuclear MedicineUniversity Hospital San PedroLogroñoSpain
  5. 5.Nuclear Medicine DepartmentMedical University of WarsawWarsawPoland
  6. 6.Therapy CommitteeEuropean Association of Nuclear MedicineViennaAustria
  7. 7.Department of Nuclear MedicineUniversity Hospital HeidelbergHeidelbergGermany
  8. 8.Clinical Cooperation Unit Nuclear MedicineDKFZHeidelbergGermany
  9. 9.Department of Nuclear MedicineThe Institute of Cancer Research and The Royal Marsden HospitalLondonUK

Personalised recommendations